The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Brazil clears emergency use of Sinovac, AstraZeneca vaccines, shots begin

Sun, 17th Jan 2021 18:28

(Adds details on doses, Sao Paulo governor comments)

By Jamie McGeever and Pedro Fonseca

BRASILIA/RIO DE JANEIRO, Jan 17 (Reuters) - Brazilian health
regulator Anvisa on Sunday approved emergency use of COVID-19
vaccines from China's Sinovac Biotech Ltd and Britain's
AstraZeneca, clearing the way for immunizations as the
pandemic enters a deadly second wave.

Minutes after Anvisa's board voted unanimously to approve
both vaccines, Monica Calazans, a 54-year-old nurse in Sao
Paulo, became the first person to be inoculated in the country,
receiving the Chinese vaccine known as CoronaVac.

President Jair Bolsonaro, a coronavirus skeptic who has
refused to take a vaccine himself, is under growing pressure to
start inoculations in Brazil, which has lost more than 200,000
to COVID-19 – the worst death toll outside the United States.
(Graphic: https://tmsnrt.rs/34pvUyi)

Delays with vaccine shipments and testing results have held
up vaccinations in the country, once a global leader in mass
immunizations and now a regional laggard after countries such as
Chile and Mexico started giving shots last month.

Bolsonaro's government aims to kick off a national
immunization program this week but is waiting on shipments of
the AstraZeneca vaccine at the center of its plans. That has
added to public frustration and offered a political rival the
chance to upstage the right-wing president.

Sao Paulo Governor Joao Doria, who oversees the Butantan
biomedical center that is partnered with Sinovac in Brazil, said
Anvisa's decision was a triumph for science as he gave the
go-ahead for the first vaccination in his state.

"A victory for science. A victory for life. A victory for
Brazil," Doria tweeted.

Bolsonaro, for whom Doria is a potential center-right rival
to his 2022 re-election efforts, has taunted the governor over
CoronaVac's disappointing 50% efficacy in Brazilian trials. But
the federal Health Ministry has agreed to acquire and distribute
the shot for the national immunization drive.

Health Minister Eduardo Pazuello told a news conference that
the rush to start vaccinating immediately was an illegal
"marketing ploy" and the government would start distributing the
vaccines to states on Monday, with the nationwide immunization
plan beginning on Wednesday.

Brazil could eventually vaccinate 1 million people a day, he
said.

Adding to the urgency for vaccinations, a second wave of the
outbreak in Brazil is snowballing as the country confronts a
new, potentially more contagious variant of the coronavirus that
originated in Amazonas state and prompted Britain and Italy to
bar entry to Brazilians.

Butantan, which is set up to fill and finish CoronaVac doses
on its production line, plans to supply 46 million doses of the
two-dose shot by April, the institute said in a statement. Some
6 million of those are ready to go.

The federally funded Fiocruz institute is still waiting for
a delayed shipment of the active ingredient in the AstraZeneca
vaccine for finishing on a Rio de Janeiro assembly line.

The Health Ministry has scrambled to line up 2 million ready
doses of the AstraZeneca vaccine from India, but officials there
have suggested it may take weeks to approve exports. Pazuello
said on Sunday he expected the doses from India this week.

(Reporting by Eduardo Simoes in Sao Paulo, Pedro Fonseca in Rio
de Janeiro, Jamie McGeever and Ricardo Brito in Brasilia;
Editing by Brad Haynes, Lisa Shumaker and Peter Cooney)

More News
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more
19 Feb 2024 08:44

LONDON MARKET OPEN: Stocks drift; Currys surges on takeover interest

(Alliance News) - Stock prices in London were looking for direction early Monday, as investors weighed possible trajectories for US interest rate cuts and a China's economic recovery.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.